|
1. |
Glucose and Insulin Metabolism in Uremia |
|
Nephron,
Volume 61,
Issue 4,
1992,
Page 377-382
Robert H.K. Mak,
Ralph A. De Fronzo,
Preview
|
PDF (1440KB)
|
|
ISSN:1660-8151
DOI:10.1159/000186953
出版商:S. Karger AG
年代:1992
数据来源: Karger
|
2. |
Immunosuppression by T Cell Antibodies in Renal Transplantation |
|
Nephron,
Volume 61,
Issue 4,
1992,
Page 383-392
Robert A.P. Koene,
Preview
|
PDF (2468KB)
|
|
ISSN:1660-8151
DOI:10.1159/000186954
出版商:S. Karger AG
年代:1992
数据来源: Karger
|
3. |
Pharmacokinetics of Recombinant Human Erythropoietin in Dialysis Patients after Single and Multiple Subcutaneous Administrations |
|
Nephron,
Volume 61,
Issue 4,
1992,
Page 393-398
D. Kampf,
K.U. Eckardt,
H.C. Fischer,
C. Schmalisch,
B. Ehmer,
M. Schostak,
Preview
|
PDF (1060KB)
|
|
摘要:
The pharmacokinetics of recombinant human erythropoietin (rhEPO) were evaluated after single intravenous and single subcutaneous administration of 40 U/kg to 8 patients with dialysis treatment. All patients suffered from renal anemia with a hematocrit ≤ 24% and were treated with 40 U/kg rhEPO subcutaneously, three times a week for 6 weeks. At the end of the treatment period, kinetics of rhEPO were repeated. After the initial subcutaneous rhEPO dose, the following results were obtained: maximum plasma concentration 39.5 (26.7-56.9) U/l, area under the curve (AUC) 1,122 (582-3,220) U · h · 1-1 and terminal half-life 13.2 (2.6-53.1) h. The corresponding data after multiple rhEPO doses were: maximum rhEPO plasma concentration 26.3 (9.4–49.1) U/l, AUC 724 (407–1,464) U·h·H and terminal half-life 14.2 (3.5-24.4) h. There were no statistical significant differences between the two investigations. From the present study, it can be concluded that after a treatment period of 6 weeks with multiple subcutaneous rhEPO doses, rhEPO absorption as well as rhEPO elimination are
ISSN:1660-8151
DOI:10.1159/000186955
出版商:S. Karger AG
年代:1992
数据来源: Karger
|
4. |
Effectiveness and Safety of Recombinant Human Erythropoietin in Predialysis Patients |
|
Nephron,
Volume 61,
Issue 4,
1992,
Page 399-403
Helmut Graf,
Preview
|
PDF (823KB)
|
|
摘要:
Experience with erythropoietin in the treatment of anemia in predialysis patients is limited. A practical treatment regimen which minimized the number of outpatient visits was investigated. The Austrian multicenter study included 123 patients. At baseline, the treatment protocol mandated once weekly the administration of 10,000 U recombinant human erythropoietin (r-HuEPO) subcutaneously. The follow-up period was 3 months, and dose adjustments were made at monthly intervals. At baseline, the mean values for creatinine were 6.2 ± 0.2 mg/dl, and for hemoglobin (Hb) 9.0 g/dl. During 3 months of therapy, mean Hb increased to 10.8 g/dl and creatinine to 6.6 mg/dl. The initial r-HuEPO weekly dose was 10,000 U. The mean dose after 3 months was 9,000 ± 4,000 U. There was no significant alteration of the slope of the reciprocal creatinine curve or of blood pressure values. No side effects occurred during the 3-month treatment period. In conclusion, the results of this multicenter trial demonstrate that using a simple once-weekly subcutaneous treatment regime, r-HuEPO can be administered safely and effectively in predialysis patient
ISSN:1660-8151
DOI:10.1159/000186956
出版商:S. Karger AG
年代:1992
数据来源: Karger
|
5. |
Anemia and Chronic Renal Failure: A Therapeutical Approach by Reduced Glutathione Parenteral Administration |
|
Nephron,
Volume 61,
Issue 4,
1992,
Page 404-408
C. Costagliola,
L. Romano,
G. Scibelli,
A. de Vincentiis,
P. Sorice,
A. Di Benedetto,
Preview
|
PDF (886KB)
|
|
摘要:
Authors report on the effect of reduced glutathione parenterally administered on the anemic status in patients suffering from chronic renal failure and undergoing hemodialysis. Twenty patients were studied for 180 days and were divided into two age- and sex-matched groups. The first group (10 patients) received placebo, the second group (10 patients) received the treatment (1,200 mg of reduced glutathione). Reduced glutathione and placebo were given for 120 days in a randomized double-blind fashion and the following measurements were performed : red blood cells reduced and oxidized glutathione, plasma reduced and oxidized glutathione, hematocrit, hemoglobin, reticulocytes, serum iron, transferrin, indirect bilirubin, urea, creatinine, calcium, phosphate, parathyroid hormone and alkaline phosphatase. In the treated group, during the supplementation period, there was an increase in the levels of red blood cells and plasma reduced glutathione, hematocrit and hemoglobin and a concomitant decrease in plasma oxidized glutathione and reticulocytes with a maximum effect on the 120th day of therapy. In the placebo-treated group there were no significant variations of the parameters considered during the study period. When the therapy, on patients undergoing treatment, was terminated there was a drop in the analyzed parameters, which fell to pretreatment values at the subsequent controls. These findings seem to indicate that reduced glutathione could represent a useful drug in the treatment and management of anemia in patients affected by chronic renal failure.
ISSN:1660-8151
DOI:10.1159/000186957
出版商:S. Karger AG
年代:1992
数据来源: Karger
|
6. |
Comparison of Lipids, Apoproteins and Associated Enzyme Activities between Diabetic and Nondiabetic End-Stage Renal Disease |
|
Nephron,
Volume 61,
Issue 4,
1992,
Page 409-414
Takashi Sakurai,
Toru Oka,
Hiroshi Hasegawa,
Naoya Igaki,
Shozo Miki,
Takeo Goto,
Preview
|
PDF (1283KB)
|
|
摘要:
Lipids, apoproteins and associated enzyme activities in type 2 diabetic end-stage renal disease (ESRD) were compared with that in nondiabetic ESRD and normal controls. Of the 40 uremic patients with non-insulin-dependent diabetes mellitus, 20 patients were receiving stable continuous hemodialysis treatment (CHT). Of the 39 patients with nondiabetic ESRD, 21 were undergoing CHT. Patients with nondiabetic ESRD exhibited elevated levels of serum triglyceride and a marked reduction in high-density-lipoprotein (HDL) cholesterol. Concentrations of serum apolipoprotein (Apo) C-3 were higher than in controls, whereas mean levels of serum Apo E were lower. The concentrations of serum Apo A-1 and Apo A-2 decreased with diminished lecithin: cholesterol acyltransferase activity. Lipoprotein lipase activity decreased in undialysed patients, and hepatic triglyceride lipase activity decreased significantly throughout the observation. Patients with diabetic ESRD exhibited elevated serum Apo B and normal serum Apo E levels, besides the lipid and Apo abnormalities observed in nondiabetic ESRD. Moreover, a prominent reduction in serum Apo A-1 was found in dialysed diabetic patients. The Apo B/Apo A-1 ratio was significantly higher in diabetic ESRD than in nondiabetic patients undergoing CHT. These results indicate that lipid abnormalities are accelerated in diabetic ESRD and may constitute a serious risk for the development of atherosclerosis.
ISSN:1660-8151
DOI:10.1159/000186958
出版商:S. Karger AG
年代:1992
数据来源: Karger
|
7. |
Heparan Sulfate Proteoglycans Are Lost in Patients with Diabetic Nephropathy |
|
Nephron,
Volume 61,
Issue 4,
1992,
Page 415-421
Hirofumi Makino,
Shuji Ikeda,
Toshinori Haramoto,
Zensuke Ota,
Preview
|
PDF (1128KB)
|
|
摘要:
The pathogenesis of diabetic nephropathy relative to the changes in the glomerular extracellular matrices was investigated. Renal tissues from 10 diabetic patients were immunostained with antibodies directed against heparan sulfate proteoglycans (HS-PGs), laminin, type IV collagen and fibronectin. Seven patients were nephrotic and had advanced glomerulosclerosis with nodular lesion, while the other 3 had no renal manifestations or minor glomerular tissue alterations. Controls included kidneys removed from patients with renal tumors and specimens obtained by renal biopsy from patients with IgA nephropathy. Relationships among proteinuria, intensity of fluorescence and glomerular changes were studied. In diabetes 3 patients with minor glomerular lesions were found to have no changes in various components of extracellular matrices. A marked reduction in the intensity of staining with anti-HS-PG antibodies was observed in renal specimens from patients with nodular glomerulosclerosis and proteinuria, while a mild decrease in the intensity of fluorescence was observed in tissues stained with antilaminin antibodies. An increase compared to normal control sample findings in type IV collagen and fibronectin was observed in the mesangium of sclerosing glomeruli. No loss of HS-PG was observed in patients with IgA nephropathy. These results indicate that glomerular extracellular matrix HS-PG is lost in association with diabetic nephropathy; this loss results in alteration of the charge-selective properties of glomerular capillaries. This alteration may, in part, be the cause of the proteinuria associated with diabetic nephropathy.
ISSN:1660-8151
DOI:10.1159/000186959
出版商:S. Karger AG
年代:1992
数据来源: Karger
|
8. |
Determinants of Intact Parathyroid Hormone and Free 1,25-Dihydroxyvitamin D Levels in Mild and Moderate Renal Failure |
|
Nephron,
Volume 61,
Issue 4,
1992,
Page 422-427
Andrew St. John,
Mark B. Thomas,
Charmian P. Davies,
Brian Mullan,
Ian Dick,
Brian Hutchison,
Agatha van der Schaff,
Richard L. Prince,
Preview
|
PDF (1148KB)
|
|
摘要:
Parameters of calcium and phosphate metabolism were measured in 27 patients with mild renal failure [glomerular filtration rate (GFR) 40-90 ml/min], 12 patients with moderate renal failure (GFR 20-39 ml/min) and in 12 healthy subjects. GFR was determined by technetium-99m diethylenetriamine pentaacetic acid clearance. Intact parathyroid hormone (PTH) was measured by a sensitive immunochemiluminometric assay and somatomedin-C was determined by radioimmunoassay. Both 1,25-dihydroxyvitamin D [1,25(OH)2D] and vitamin-D-binding protein were measured allowing calculation of the free 1,25(OH)2D index. By linear regression and multivariate analysis, PTH was negatively and independently correlated with GFR, plasma bicarbonate and 25-hydroxyvitamin D [25(OH)D] while free 1,25(OH)2D was positively correlated with GFR. Increased PTH secretion and reductions in 1,25(OH)2D were present in mild renal failure patients before any changes in plasma calcium, phosphate and bicarbonate were noted. Plasma alkaline phosphatase was significantly higher in mild chronic renal failure patients compared to normal subjects, possibly indicating early effects of the secondary hyperparathyroidism on the skeleton. Somatomedin-C did not correlate with the free 1,25(OH)2D index or a measure of 1,25(OH)2D production. It is concluded that the secondary hyperparathyroidism which occurs very early in the onset of chronic renal failure may be due to a reduction in the circulating concentration of 1,25(OH)2D consequent upon the renal failure. Low plasma bicarbonate and 25(OH)D also appear to be determinants of a raised PTH concentration. The compensatory increase in PTH presumably maintains extracellular calcium and phosphate levels constant but with possible deleterious effects on the skeleton.
ISSN:1660-8151
DOI:10.1159/000186960
出版商:S. Karger AG
年代:1992
数据来源: Karger
|
9. |
Decreased Renal Clearance of Xanthine and Hypoxanthine in a Patient with Renal Hypouricemia: A New Defect in Renal Handling of Purines |
|
Nephron,
Volume 61,
Issue 4,
1992,
Page 428-431
Masanori Kawachi,
Norio Kono,
Hiroaki Kiyokawa,
Ikuo Mineo,
Hiromu Nakajima,
Takao Shimizu,
Shiro Yorifuji,
Masamichi Kuwajima,
Seiichiro Tarui,
Preview
|
PDF (795KB)
|
|
摘要:
Renal handling of urate, xanthine and hypoxanthine was studied in a hypouricemic patient who had increased plasma concentrations of xanthine and hypoxanthine. The patient, a 50-year-old man, had been suffering from Parkinson’s disease, while neither systemic disorders nor particular renal diseases known to affect plasma purine levels were found. His serum urate level was 58 ± 6 μmol/l (healthy controls for males, 310 ± 48 μmol/l, mean ± SD) and the renal uric acid clearance was 3 times higher than that of the controls, establishing a diagnosis of renal hypouricemia. Xanthine and hypoxanthine concentrations in the plasma were elevated to 1.3 ± 0.1 μmol/l (controls, 0.5 ± 0.3) and 5.9 ± 3.5 μmol/l (controls, 1.6 ± 0.4), respectively. Both renal xanthine and hypoxanthine clearance was only half the value of the controls, indicating reduced urinary excretion of xanthine, and hypoxanthine appears to be responsible for their elevation in plasma. A probenecid loading test revealed no response of urinary urate excretion but normal responses of xanthine and hypoxanthine excretion. However, urinary excretion of urate, xanthine or hypoxanthine did not respond at all to pyrazinamide administration. These findings indicate that the patient had a defective renal handling of xanthine and hypoxanthine as w
ISSN:1660-8151
DOI:10.1159/000186961
出版商:S. Karger AG
年代:1992
数据来源: Karger
|
10. |
Two Cases in Whom Pyrazinamide Does Not Inhibit the Uricosuric Action of Benzbromarone |
|
Nephron,
Volume 61,
Issue 4,
1992,
Page 432-434
Tetsuya Yamamoto,
Yuji Moriwaki,
Sumio Takahashi,
Michio Suda,
Emmanuel Oluyemi Agbedana,
Kazuya Higashino,
Preview
|
PDF (522KB)
|
|
摘要:
The 2 subjects were a diabetic male with renal hypouricemia and a healthy male with normouricemia. In these subjects, 200 mg of benzbromarone increased fractional uric acid clearance (FUa) and 3.0 g of pyrazinamide decreased FUa. However, pyrazinamide did not inhibit the uricosuric action of benzbromarone at all on the administration of 3.0 g of pyrazinamide together with 200 mg of benzbromarone. These results indicated that in these cases, the relative role of each component could not be determined on the basis of the hypothetical four-component model.
ISSN:1660-8151
DOI:10.1159/000186962
出版商:S. Karger AG
年代:1992
数据来源: Karger
|
|